55.84
-0.28 (-0.50%)
| Penutupan Terdahulu | 56.12 |
| Buka | 55.24 |
| Jumlah Dagangan | 602,331 |
| Purata Dagangan (3B) | 507,557 |
| Modal Pasaran | 3,431,764,480 |
| Harga / Jualan (P/S) | 33.30 |
| Harga / Buku (P/B) | 339.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | -230.11% |
| Margin Operasi (TTM) | -131.98% |
| EPS Cair (TTM) | -4.32 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 47.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 74.18% |
| Nisbah Semasa (MRQ) | 3.49 |
| Aliran Tunai Operasi (OCF TTM) | -124.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -143.16 M |
| Pulangan Atas Aset (ROA TTM) | -46.24% |
| Pulangan Atas Ekuiti (ROE TTM) | -147.90% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Rhythm Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.38 |
|
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.53% |
| % Dimiliki oleh Institusi | 115.30% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (Canaccord Genuity, 43.27%) | Beli |
| Median | 69.00 (23.57%) | |
| Rendah | 52.00 (B of A Securities, -6.88%) | Pegang |
| Purata | 68.56 (22.78%) | |
| Jumlah | 8 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 56.86 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Dec 2024 | 69.00 (23.57%) | Beli | 56.04 |
| 04 Dec 2024 | 69.00 (23.57%) | Beli | 60.37 | |
| JMP Securities | 23 Dec 2024 | 75.00 (34.31%) | Beli | 56.04 |
| Oppenheimer | 20 Dec 2024 | 76.00 (36.10%) | Beli | 56.12 |
| Goldman Sachs | 05 Dec 2024 | 66.00 (18.19%) | Beli | 57.82 |
| Canaccord Genuity | 19 Nov 2024 | 80.00 (43.27%) | Beli | 59.97 |
| 06 Nov 2024 | 80.00 (43.27%) | Beli | 62.65 | |
| Needham | 06 Nov 2024 | 64.00 (14.61%) | Beli | 62.65 |
| 30 Oct 2024 | 55.00 (-1.50%) | Beli | 49.54 | |
| TD Cowen | 06 Nov 2024 | 65.00 (16.40%) | Beli | 62.65 |
| Guggenheim | 21 Oct 2024 | 70.00 (25.36%) | Beli | 50.19 |
| B of A Securities | 14 Oct 2024 | 52.00 (-6.88%) | Pegang | 50.24 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |